Two heart disease medtech firms among Nasdaq debutants
This article was originally published in Clinica
Executive Summary
A flurry of end-of-year initial public offerings (IPOs) has included a handful of medical technology debutants. Conor Medsystems, which is developing a new design of drug-eluting stent aimed at providing better control over the release of the drug than existing drug-coated devices was the most recent.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.